ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Michael A LissDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas.ORCID 0000-0001-6978-1026
Nicole ZeltserDepartment of Human Genetics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0001-7246-2771
Yingye ZhengDepartment of Biostatistics, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-3078-4200
Camden LopezDepartment of Biostatistics, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-4516-8088
Menghan LiuDepartment of Biostatistics, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0000-7436-3056
Yash PatelJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-3113-7010
Takafumi N YamaguchiDepartment of Human Genetics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-1082-3871
Stefan E EngJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-5245-6507
Mao TianDepartment of Human Genetics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-4418-5153
Oliver J SemmesDepartment of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, Virginia.ORCID 0000-0001-9927-4869
Daniel W LinDivision of Public Health Sciences, Department of Urology, Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington.ORCID 0000-0002-2135-1534
James D BrooksDepartment of Urology, Stanford University, Palo Alto, California.ORCID 0000-0003-4521-7505
John T WeiDepartment of Urology, University of Michigan, Ann Arbor, Michigan.ORCID 0009-0000-1270-6690
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.ORCID 0000-0002-1783-0698
Ashutosh K TewariDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-3146-4524
Juan Miguel MosqueraDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-4666-6476
Francesca KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-7238-8604
Brian D RobinsonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-5374-890X
Muhammad AasadDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0009-0007-3079-5755
Dean A TroyerDepartment of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, Virginia.ORCID 0000-0002-0337-5890
Jacob KaganDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.ORCID 0009-0001-2717-8613
Ian M ThompsonThe Children's Hospital of San Antonio Foundation and Christus Health, San Antonio, Texas.ORCID 0000-0003-0833-952X
Paul C BoutrosDepartment of Human Genetics, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-0553-7520
Robin J LeachDepartment of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, Texas.ORCID 0000-0002-3201-5579
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
The Early Detection Research Network: Data Management and Coordinating CenterU24CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RUTH D ETZIONI, Ziding Feng · 2010 to 2026
$75.7M
SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CAU01CA086402 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LEACH, ROBIN JEAN, THOMPSON, IAN M. · 2000 to 2018
$33.1M
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4M
Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9M
Training Grant in Genomic Analysis and InterpretationT32HG002536 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Valerie A Arboleda, Harold Pimentel · 2002 to 2026
$8.6M
PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer ResearchU01CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2019 to 2023
$5.4M
Virginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · NCI · OLD DOMINION UNIVERSITY · PI Paul Christopher Boutros, OLIVER John SEMMES · 2022 to 2026
$3.2M
Germline Determinants of Prostate Cancer EvolutionR01CA270108 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAUL T. SPELLMAN · 2023 to 2026
$2.9M
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate CancerU01CA214194 · NCI · EASTERN VIRGINIA MEDICAL SCHOOL · PI BOUTROS, PAUL CHRISTOPHER, KISLINGER, THOMAS · 2016 to 2021
$2.5M
Predicting prostate cancer clinical outcomes with germline genomic biomarkersF31CA281168 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZELTSER, NICOLE · 2024 to 2025
$83k
National Cancer Institute (NCI) P30CA016042National Cancer Institute (NCI) P50CA211024National Cancer Institute (NCI) R01CA270108National Cancer Institute (NCI) U01CA086402National Cancer Institute (NCI) U01CA113913National Cancer Institute (NCI) U24CA086368National Cancer Institute (NCI) U2CCA271894National Human Genome Research Institute (NHGRI) T32HG002536NCI NIH HHS F31 CA281168NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA270108NCI NIH HHS U01 CA086402NCI NIH HHS U01 CA113913NCI NIH HHS U01 CA182883NCI NIH HHS U01 CA214194NCI NIH HHS U24 CA086368NCI NIH HHS U2C CA271894NHGRI NIH HHS T32 HG002536U.S. Department of Defense (DOD) W81XWH-15-1-0441U.S. Department of Defense (DOD) W81XWH-22-1-0247
6 · The paper itself
Abstract
backgroundLocalized prostate tumors show significant spatial heterogeneity, with regions of high-grade disease adjacent to lower grade disease. Consequently, prostate cancer biopsies are prone to sampling bias, potentially leading to underestimation of tumor grade. To study the clinical, epidemiologic, and molecular hallmarks of this phenomenon, we conducted a prospective study of grade upgrading: differences in detected prostate cancer grade between biopsy and surgery.
methodsWe established a prospective, multi-institutional cohort of men with grade group 1 (GG1) prostate cancer on biopsy who underwent radical prostatectomy. Upgrading was defined as detection of GG2+ in the resected tumor. Germline DNA from 192 subjects was subjected to whole-genome sequencing to quantify ancestry, pathogenic variants in DNA damage response genes, and polygenic risk.
resultsOf 285 men, 67% upgraded at surgery. PSA density and percent of cancer in pre-prostatectomy positive biopsy cores were significantly associated with upgrading. No assessed genetic risk factor was predictive of upgrading, including polygenic risk scores for prostate cancer diagnosis.
conclusionsIn a cohort of patients with low-grade prostate cancer, a majority upgraded at radical prostatectomy. PSA density and percent of cancer in pre-prostatectomy positive biopsy cores portended the presence of higher-grade disease, while germline genetics was not informative in this setting. Patients with low-risk prostate cancer, but elevated PSA density or percent cancer in positive biopsy cores, may benefit from repeat biopsy, additional imaging or other approaches to complement active surveillance. IMPACT: Further risk stratification of patients with low-risk prostate cancer may provide useful context for active surveillance decision-making.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. · full record | OpenQuestion